Hastings TG
Because the vial size and reconstitution volume both affect the final concentration, researchers must recalculate the GHK-Cu dosing conversion whenever they change either variable
longer cycles raise copper-accumulation concern from GHK-Cu
Rinonapoli G, Pace V, Ruggiero C, Ceccarini P, Bisaccia M, Meccariello L, et al
For recovery enhancement, performance optimisation, or longevity goals in healthy people, until a randomised, placebo-controlled trial in a defined population with an objective primary endpoint and pharmacovigilance over a clinically meaningful duration produces data we do not currently have, we just don't have good evidence of benefit, let alone safety